Why Dynavax Technologies Corporation Stock Cratered in 2019
Dynavax Technologies Corporation (NASDAQ: DVAX), an early commercial-stage vaccine maker, had an extremely rough 2019. Specifically, the biotech's shares lost a staggering 37.5% of their value last year, according to data from S&P Global Market Intelligence.
Dynavax's stock took a beating in 2019 for two major reasons. First off, the company decided to jettison its promising oncology program. The move was reportedly made in order to beef up the commercial launch of the company's hepatitis B vaccine, Heplisav-B. Prior to this strategic decision, though, some shareholders were hoping that the company's cancer assets would attract a deep-pocketed partner -- or perhaps even a buyout offer.
Image source: Getty Images.
Source Fool.com
